UA75136C2 - A modified cyclosporine which can be used as prodrugs. and application thereof - Google Patents

A modified cyclosporine which can be used as prodrugs. and application thereof Download PDF

Info

Publication number: UA75136C2
Authority: UA; Ukraine
Prior art keywords: mei; substituents; mai; aia; group
Prior art date: 2001-04-20

Application number

UA20031110436A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Debiopharm Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-20

Filing date

2002-04-22

Publication date

2006-03-15

2002-04-22 Application filed by Debiopharm Sa filed Critical Debiopharm Sa

2006-03-15 Publication of UA75136C2 publication Critical patent/UA75136C2/uk

Links

239000000651 prodrug Substances 0.000 title claims abstract description 54
229940002612 prodrug Drugs 0.000 title claims abstract description 54
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title description 67
229940064638 modified cyclosporine Drugs 0.000 title 1
125000004122 cyclic group Chemical group 0.000 claims abstract description 56
125000001424 substituent group Chemical group 0.000 claims abstract description 38
125000000217 alkyl group Chemical group 0.000 claims abstract description 34
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 28
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 20
125000000539 amino acid group Chemical group 0.000 claims abstract description 19
125000002877 alkyl aryl group Chemical group 0.000 claims abstract description 16
125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 15
125000000623 heterocyclic group Chemical group 0.000 claims abstract description 13
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 13
150000003839 salts Chemical class 0.000 claims abstract description 13
125000004404 heteroalkyl group Chemical group 0.000 claims abstract description 11
229910052799 carbon Inorganic materials 0.000 claims abstract description 7
150000001413 amino acids Chemical class 0.000 claims description 31
238000002360 preparation method Methods 0.000 claims description 20
238000011282 treatment Methods 0.000 claims description 17
-1 alkylheterocycle Chemical group 0.000 claims description 15
206010023332 keratitis Diseases 0.000 claims description 11
230000001575 pathological effect Effects 0.000 claims description 11
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 9
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
229940126601 medicinal product Drugs 0.000 claims description 7
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 6
230000009471 action Effects 0.000 claims description 6
210000004400 mucous membrane Anatomy 0.000 claims description 4
206010057380 Allergic keratitis Diseases 0.000 claims description 3
206010010741 Conjunctivitis Diseases 0.000 claims description 3
208000031886 HIV Infections Diseases 0.000 claims description 3
208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
206010052779 Transplant rejections Diseases 0.000 claims description 3
125000004429 atom Chemical group 0.000 claims description 3
239000003246 corticosteroid Substances 0.000 claims description 3
229960001334 corticosteroids Drugs 0.000 claims description 3
239000001257 hydrogen Substances 0.000 claims description 3
229910052739 hydrogen Inorganic materials 0.000 claims description 3
230000002197 limbic effect Effects 0.000 claims description 3
JLESVLCTIOAHPT-UHFFFAOYSA-N mmai Chemical compound C1=C(C)C(OC)=CC2=C1CC(N)C2 JLESVLCTIOAHPT-UHFFFAOYSA-N 0.000 claims description 3
210000003097 mucus Anatomy 0.000 claims description 3
210000000056 organ Anatomy 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
230000010076 replication Effects 0.000 claims description 3
208000025889 stromal keratitis Diseases 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
241000158723 Melia Species 0.000 claims description 2
210000001185 bone marrow Anatomy 0.000 claims description 2
210000002216 heart Anatomy 0.000 claims description 2
201000010666 keratoconjunctivitis Diseases 0.000 claims description 2
210000003734 kidney Anatomy 0.000 claims description 2
210000004185 liver Anatomy 0.000 claims description 2
230000007774 longterm Effects 0.000 claims description 2
210000004072 lung Anatomy 0.000 claims description 2
210000000496 pancreas Anatomy 0.000 claims description 2
210000000813 small intestine Anatomy 0.000 claims description 2
230000004083 survival effect Effects 0.000 claims description 2
230000005764 inhibitory process Effects 0.000 claims 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 2
125000005343 heterocyclic alkyl group Chemical group 0.000 abstract 2
108010036949 Cyclosporine Proteins 0.000 description 66
229930105110 Cyclosporin A Natural products 0.000 description 50
229960001265 ciclosporin Drugs 0.000 description 49
239000000243 solution Substances 0.000 description 38
229930182912 cyclosporin Natural products 0.000 description 32
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 17
150000001875 compounds Chemical class 0.000 description 16
238000006243 chemical reaction Methods 0.000 description 15
238000003756 stirring Methods 0.000 description 15
108010036941 Cyclosporins Proteins 0.000 description 14
239000000126 substance Substances 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
239000007864 aqueous solution Substances 0.000 description 12
239000012074 organic phase Substances 0.000 description 12
239000004473 Threonine Substances 0.000 description 11
239000012043 crude product Substances 0.000 description 11
239000012047 saturated solution Substances 0.000 description 11
239000011541 reaction mixture Substances 0.000 description 10
239000000741 silica gel Substances 0.000 description 10
229910002027 silica gel Inorganic materials 0.000 description 10
239000002904 solvent Substances 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
238000001990 intravenous administration Methods 0.000 description 9
239000008194 pharmaceutical composition Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 9
239000003814 drug Substances 0.000 description 8
239000006260 foam Substances 0.000 description 8
230000000622 irritating effect Effects 0.000 description 8
238000003776 cleavage reaction Methods 0.000 description 7
239000012530 fluid Substances 0.000 description 7
230000007017 scission Effects 0.000 description 7
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
235000019439 ethyl acetate Nutrition 0.000 description 6
239000000203 mixture Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
239000012300 argon atmosphere Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
239000004359 castor oil Substances 0.000 description 5
235000019438 castor oil Nutrition 0.000 description 5
230000000694 effects Effects 0.000 description 5
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
238000000034 method Methods 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
229940124597 therapeutic agent Drugs 0.000 description 5
230000009466 transformation Effects 0.000 description 5
RTYBPTOWYZMRRS-UHFFFAOYSA-N 2-(2-carboxyoxy-5-nitrophenyl)ethyl acetate Chemical compound CC(=O)OCCC1=CC([N+]([O-])=O)=CC=C1OC(O)=O RTYBPTOWYZMRRS-UHFFFAOYSA-N 0.000 description 4
208000003556 Dry Eye Syndromes Diseases 0.000 description 4
206010013774 Dry eye Diseases 0.000 description 4
108090000371 Esterases Proteins 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
238000007385 chemical modification Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
241000700159 Rattus Species 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000012634 fragment Substances 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
229920000724 poly(L-arginine) polymer Polymers 0.000 description 3
239000002243 precursor Substances 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
230000003381 solubilizing effect Effects 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108010069514 Cyclic Peptides Proteins 0.000 description 2
102000001189 Cyclic Peptides Human genes 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
206010047513 Vision blurred Diseases 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
210000000795 conjunctiva Anatomy 0.000 description 2
210000004087 cornea Anatomy 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 2
NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
239000004530 micro-emulsion Substances 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
108010011110 polyarginine Proteins 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000006257 total synthesis reaction Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
JTOKYIBTLUQVQV-QRVTZXGZSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-[(1r)-1-hydroxyethyl]-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontan Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H]([C@@H](C)O)NC1=O JTOKYIBTLUQVQV-QRVTZXGZSA-N 0.000 description 1
UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
AQOSPGCCTHGZFL-UHFFFAOYSA-N 1-(3a-hydroxy-7-methoxy-1,2,4,8b-tetrahydropyrrolo[2,3-b]indol-3-yl)ethanone Chemical compound COC1=CC=C2NC3(O)N(C(C)=O)CCC3C2=C1 AQOSPGCCTHGZFL-UHFFFAOYSA-N 0.000 description 1
MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
SVDDJQGVOFZBNX-UHFFFAOYSA-N 2-chloroethyl carbonochloridate Chemical compound ClCCOC(Cl)=O SVDDJQGVOFZBNX-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
206010010726 Conjunctival oedema Diseases 0.000 description 1
206010011026 Corneal lesion Diseases 0.000 description 1
JTOKYIBTLUQVQV-UHFFFAOYSA-N Cyclosporin C Natural products CC=CCC(C)C(O)C1N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(C(C)O)NC1=O JTOKYIBTLUQVQV-UHFFFAOYSA-N 0.000 description 1
108010002156 Depsipeptides Proteins 0.000 description 1
101000985278 Escherichia coli 5-carboxymethyl-2-hydroxymuconate Delta-isomerase Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
102100040448 Leukocyte cell-derived chemotaxin 1 Human genes 0.000 description 1
241001446467 Mama Species 0.000 description 1
102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
230000030833 cell death Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
108010019248 cyclosporin C Proteins 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
239000010432 diamond Substances 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000004955 epithelial membrane Anatomy 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
229960002390 flurbiprofen Drugs 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000004519 grease Substances 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
229960004184 ketamine hydrochloride Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
229940127554 medical product Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
229940078547 methylserine Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
231100001180 nonmyelotoxic Toxicity 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229940063122 sandimmune Drugs 0.000 description 1
238000011894 semi-preparative HPLC Methods 0.000 description 1
230000035807 sensation Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
231100000456 subacute toxicity Toxicity 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
150000003587 threonine derivatives Chemical class 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Virology (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UA20031110436A 2001-04-20 2002-04-22 A modified cyclosporine which can be used as prodrugs. and application thereof UA75136C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH7202001		2001-04-20
PCT/CH2002/000222 WO2002085928A2 (fr)	2001-04-20	2002-04-22	Cyclosporine modifiee utilisable en tant que pro-drogue et son utilisation

Publications (1)

Publication Number	Publication Date
UA75136C2 true UA75136C2 (en)	2006-03-15

Family

ID=4531478

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20031110436A UA75136C2 (en)	2001-04-20	2002-04-22	A modified cyclosporine which can be used as prodrugs. and application thereof

Country Status (17)

Country	Link
US (1)	US6995139B2 (de)
EP (1)	EP1379547B1 (de)
JP (1)	JP4588979B2 (de)
KR (1)	KR100932859B1 (de)
CN (1)	CN1507451A (de)
AT (1)	ATE313557T1 (de)
AU (1)	AU2002245996B8 (de)
BR (1)	BR0208923A (de)
CA (1)	CA2444278C (de)
DE (1)	DE60208180T2 (de)
ES (1)	ES2256450T3 (de)
IL (1)	IL158385A0 (de)
MX (1)	MXPA03009586A (de)
RU (1)	RU2290196C2 (de)
UA (1)	UA75136C2 (de)
WO (1)	WO2002085928A2 (de)
ZA (1)	ZA200307794B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7232924B2 (en)	2001-06-11	2007-06-19	Xenoport, Inc.	Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en)	2005-04-06	2011-11-01	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en)	2001-06-11	2004-11-16	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en)	2001-06-11	2007-03-06	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US7354574B2 (en) *	2002-11-07	2008-04-08	Advanced Ocular Systems Limited	Treatment of ocular disease
US7538084B2 (en)	2003-03-17	2009-05-26	Amr Technology, Inc.	Cyclosporins
US7083803B2 (en)	2003-09-19	2006-08-01	Advanced Ocular Systems Limited	Ocular solutions
US7087237B2 (en)	2003-09-19	2006-08-08	Advanced Ocular Systems Limited	Ocular solutions
WO2006115509A2 (en)	2004-06-24	2006-11-02	Novartis Vaccines And Diagnostics Inc.	Small molecule immunopotentiators and assays for their detection
JP2008514701A (ja)	2004-09-29	2008-05-08	エーエムアールテクノロジーインコーポレイテッド	シクロスポリンアルキン類似体およびそれらの薬学的使用
JP2008514702A (ja)	2004-09-29	2008-05-08	エーエムアールテクノロジーインコーポレイテッド	新規シクロスポリン類似体およびそれらの薬学的使用
JP2008515886A (ja)	2004-10-06	2008-05-15	エーエムアールテクノロジーインコーポレイテッド	シクロスポリンアルキンおよびそれらの医用薬剤としての有用性
EP1904056B1 (de)	2005-07-18	2009-04-29	Minu, L.L.C.	Verwendung von Makroliden zur Wiederherstellung der Kornealempfindungen
US7696166B2 (en)	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en)	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
WO2008013860A2 (en) *	2006-07-28	2008-01-31	Xenoport, Inc.	Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
US8394763B2 (en)	2007-09-26	2013-03-12	Oregon Health & Science University	Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009098533A1 (en) *	2008-02-08	2009-08-13	Debiopharm Sa	Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy
GB0912584D0 (en) *	2009-07-20	2009-08-26	Ucl Business Plc	Cyclosporin conjugates
BR112013014890B1 (pt)	2010-12-15	2023-10-24	Contravir Pharmaceuticals, Inc	Composto análogo de moléculas pertencentes à família ciclosporina, composição farmacêutica compreendendo o mesmo, uso terapêutico ou profilático do referido composto e processos para a preparação dos mesmos
AR090964A1 (es) *	2012-05-09	2014-12-17	Novartis Ag	Proceso para la elaboracion de undecapeptidos ciclicos
CN113388002A (zh) *	2021-06-10	2021-09-14	梯尔希（南京）药物研发有限公司	一种环孢菌素相关化合物的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE54936B1 (en) *	1980-02-14	1990-03-28	Sandoz Ltd	A method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
US4396542A (en) *	1980-02-14	1983-08-02	Sandoz Ltd.	Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
US5169773A (en) *	1984-10-04	1992-12-08	Sandoz Ltd.	Monoclonal antibodies to cyclosporins
EP0177654B1 (de) *	1984-10-10	1989-05-31	Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France	Synergistische empfängnisverhütende Mischung
US4764503A (en) *	1986-11-19	1988-08-16	Sandoz Ltd.	Novel cyclosporins
GB8717300D0 (en) *	1987-07-22	1987-08-26	Nat Res Dev	Cyclosporins
HU201577B (en) *	1988-12-20	1990-11-28	Gyogyszerkutato Intezet	Process for producing cyclosporin antibiotics
GB9116836D0 (en) *	1991-08-05	1991-09-18	Sandoz Ltd	Organic compounds
FI111730B (fi) *	1990-11-02	2003-09-15	Novartis Ag	Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
GB9204466D0 (en) *	1992-03-02	1992-04-15	Sandoz Ltd	Improvements in or relating to organic compounds
US6187547B1 (en) *	1993-09-08	2001-02-13	Novartis Ag	Assay kit
GB9624038D0 (en) *	1996-11-19	1997-01-08	Sandoz Ltd	Organic compounds
US6017879A (en) *	1998-04-03	2000-01-25	B.M.R.A. Corporation B.V.	Template associated NPY Y2-receptor agonists
AU759480B2 (en)	1998-07-01	2003-04-17	Debiopharm S.A.	Novel cyclosporin with improved activity profile
US6204257B1 (en) *	1998-08-07	2001-03-20	Universtiy Of Kansas	Water soluble prodrugs of hindered alcohols
WO2000046239A1 (fr) *	1999-02-05	2000-08-10	Debiopharm S.A.	Derives de cyclosporine et procede de preparation desdits derives
US6765019B1 (en) *	1999-05-06	2004-07-20	University Of Kentucky Research Foundation	Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
WO2001005819A1 (en) *	1999-07-15	2001-01-25	Kuhnil Pharm. Co., Ltd.	Novel water soluble-cyclosporine conjugated compounds
US6593292B1 (en) *	1999-08-24	2003-07-15	Cellgate, Inc.	Compositions and methods for enhancing drug delivery across and into epithelial tissues

2002
- 2002-04-22 US US10/474,396 patent/US6995139B2/en not_active Expired - Fee Related
- 2002-04-22 UA UA20031110436A patent/UA75136C2/uk unknown
- 2002-04-22 EP EP02713992A patent/EP1379547B1/de not_active Expired - Lifetime
- 2002-04-22 AT AT02713992T patent/ATE313557T1/de not_active IP Right Cessation
- 2002-04-22 AU AU2002245996A patent/AU2002245996B8/en not_active Ceased
- 2002-04-22 BR BR0208923-8A patent/BR0208923A/pt active Search and Examination
- 2002-04-22 JP JP2002583454A patent/JP4588979B2/ja not_active Expired - Fee Related
- 2002-04-22 ES ES02713992T patent/ES2256450T3/es not_active Expired - Lifetime
- 2002-04-22 IL IL15838502A patent/IL158385A0/xx not_active IP Right Cessation
- 2002-04-22 CN CNA028094050A patent/CN1507451A/zh active Pending
- 2002-04-22 CA CA2444278A patent/CA2444278C/en not_active Expired - Fee Related
- 2002-04-22 WO PCT/CH2002/000222 patent/WO2002085928A2/fr not_active Ceased
- 2002-04-22 RU RU2003133742/15A patent/RU2290196C2/ru not_active IP Right Cessation
- 2002-04-22 MX MXPA03009586A patent/MXPA03009586A/es active IP Right Grant
- 2002-04-22 DE DE60208180T patent/DE60208180T2/de not_active Expired - Lifetime
2003
- 2003-10-06 ZA ZA200307794A patent/ZA200307794B/en unknown
- 2003-10-17 KR KR1020037013666A patent/KR100932859B1/ko not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1379547A2 (de)	2004-01-14
KR100932859B1 (ko)	2009-12-23
CN1507451A (zh)	2004-06-23
IL158385A0 (en)	2004-05-12
KR20030094357A (ko)	2003-12-11
ATE313557T1 (de)	2006-01-15
ES2256450T3 (es)	2006-07-16
RU2290196C2 (ru)	2006-12-27
AU2002245996B8 (en)	2005-07-14
DE60208180T2 (de)	2006-08-17
ZA200307794B (en)	2004-07-19
DE60208180D1 (de)	2006-01-26
RU2003133742A (ru)	2005-03-20
US6995139B2 (en)	2006-02-07
WO2002085928A2 (fr)	2002-10-31
CA2444278A1 (en)	2002-10-31
JP2004536051A (ja)	2004-12-02
AU2002245996B2 (en)	2005-06-30
JP4588979B2 (ja)	2010-12-01
CA2444278C (en)	2011-11-22
MXPA03009586A (es)	2004-05-24
BR0208923A (pt)	2004-04-27
EP1379547B1 (de)	2005-12-21
WO2002085928A3 (fr)	2003-04-17
US20040138108A1 (en)	2004-07-15

Publication	Publication Date	Title
UA75136C2 (en)	2006-03-15	A modified cyclosporine which can be used as prodrugs. and application thereof
AU670381B2 (en)	1996-07-11	Thrombin inhibitors
CN103665107B (zh)	2017-07-14	同时具溶血栓、清除自由基和血栓靶向功能的新颖化合物及其制备方法和用途
TW403731B (en)	2000-09-01	New peptides derivatives
AU2005292162B2 (en)	2011-11-10	3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US20230312644A1 (en)	2023-10-05	Compounds having triple activities of thrombolysis, antithrombotic and radical scavenging
SA91110205B1 (ar)	2004-08-07	مشتقات سيكلوسبورين cyclo -sporin
JPS63165374A (ja)	1988-07-08	２，３−ジ置換イソオキサゾリジン類
US5721213A (en)	1998-02-24	Peptides, active as inhibitors of platelet aggregation
KR20010014267A (ko)	2001-02-26	맥관형성에 작용하는 시클릭 아자펩티드
JPH04338331A (ja)	1992-11-25	γ−ラクトン免疫抑制剤
ES2234568T3 (es)	2005-07-01	Uso de derivados de sulfoquinovesidialcilglicerol como agentes inmunosupresores.
CA2601202C (en)	2015-06-09	New hybrid oligomers, their preparation process and pharmaceutical compositions containing them
MXPA01007130A (es)	2002-04-24	Medios de contraste para angiografia.
EP0687686A1 (de)	1995-12-20	Aureobasidine
JPWO1995018147A1 (ja)	1996-04-30	オーレオバシジン類
JP3874372B2 (ja)	2007-01-31	制癌剤の効果増強剤
CN1325473C (zh)	2007-07-11	吖糖衍生物和以其为有效成分的药剂
CN101400352A (zh)	2009-04-01	用于治疗和预防疾病的组合物和方法
JPH07278187A (ja)	1995-10-24	シクロスポリン類のリン酸エステル誘導体及び医薬組成物
JPH08217793A (ja)	1996-08-27	ペプチドの製造法及びそれに用いる中間体
JPH07242563A (ja)	1995-09-19	ガン転移抑制剤